Abbisko (2256 HK)

Analysis

Health Care • China

Abbisko Cayman Limited is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule oncology therapies. Its pipeline includes core product candidates like ABSK011 (Irpagratinib) for hepatocellular carcinoma and ABSK091 (Fexagratinib) for urothelial and gastric cancers, along with Pimicotinib (ABSK021) for tenosynovial giant cell tumors. The company was founded in 2016 and is headquartered in Shanghai, China.

Refresh

Exchange Announcement • 14 Oct 2026 19:17

Next Day Disclosure Returns

Exchange Announcement • 08 Oct 2026 19:35

Next Day Disclosure Returns

Exchange Announcement • 07 Oct 2026 18:10

Next Day Disclosure Returns

Exchange Announcement • 06 Oct 2026 19:16

Next Day Disclosure Returns

Exchange Announcement • 05 Oct 2026 18:57

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00